Bannerbild German Brest Group

Presseinformationen der German Breast Group

Als unabhängiges Forschungsinstitut informieren wir zu unserer Forschungstätigkeit, unseren Veranstaltungen sowie zu wichtigen Neuigkeiten aus unserem Netzwerk.

LONG-TERM EFFICACY DATA FROM THE PHASE III GEPARSEPTO STUDY IN HIGH RISK EARLY BREAST CANCER PATIENTS

-- Phase III Secondary Endpoint Results Demonstrate A Significantly Higher Disease-free Survival Rate following nab-paclitaxel as Investigational Therapy in Neoadjuvant Breast Cancer --

Neu-Isenburg/Frankfurt, Germany and Summit, New Jersey — December 7, 2017 — The German Breast Group (GBG), the German Gynecological Oncology Working Group-Breast (AGO-B) and Celgene Corporation today announced long-term invasive disease-free survival results from the GeparSepto clinical trial comparing the investigational use of nab-paclitaxel (ABRAXANE®) to solvent-based paclitaxel in early high-risk breast cancer patients at the 2017 San Antonio Breast Cancer Symposium (SABCS). The results from the 1,206 patient study found that nab-paclitaxel demonstrated a significantly higher disease-free survival rate in high risk early breast cancer patients when compared to conventional solvent-based paclitaxel.

Press release SABCS 2015 - Updated Phase III Results from the GeparSepto trial

"nab-Paclitaxel at a dose of 125 mg/m² weekly is equally efficacious but less toxic than at 150 mg/m²"

Results from the neoadjuvant randomized GeparSepto study (GBG 69)" abstract P1-14-11

Updated Phase III Results from German Breast Group (GBG) Demonstrate Reduced Dose of Nab-Paclitaxel (ABRAXANE®) Maintains Efficacy while it Improves Tolerability in High-Risk Early Breast Cancer

SAN ANTONIO & NEU-ISENBURG, Germany & FRANKFURT, Germany -- The German Breast Group (GBG) said less may be more when it comes to the dose of innovative pharmaceuticals used to treat cancer. A follow-up to a Phase III trial presented at last year's San Antonio Breast Cancer Symposium (SABCS) demonstrated a lower dose of nab-paclitaxel (ABRAXANE®) (125mg/m2/week) maintains efficacy and is less toxic than a higher dose (150mg/m2/week) that was the starting point in the study. Both doses demonstrated improved efficacy compared to conventional paclitaxel, a taxane commonly used to treat many forms of cancer.

Press release, 5pm CT, Dec 9th, 2015

Press release SABCS 2015 - Results from the GeparSixto trial

Adding Carboplatin to Presurgery Chemotherapy Improved Disease-free Survival for Patients With Triple-negative Breast Cancer Previous results from GeparSixto showed carboplatin also increased pathologic complete responses

SAN ANTONIO — Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer (TNBC), according to results from the randomized phase II GeparSixto clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8–12.

Press release, 3:15pm CT, Dec 9th, 2015

Press release ASCO 2015 - Treatment Predictors

Abstract No: 1004, Monday June 1, 3:00 PM to 6:00 PM

Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC – Results from GeparSixto.

Abstract No: 51, Sunday May 31, 11:30 AM to 1:00 PM


PIK3CA mutation correlates with pathological complete response in primary HER2-positive breast cancer – combined analysis of 967 patients from three prospective clinical trials

Press release - German Breast Group (GBG) Studies Demonstrate Subanalyses of Tumor DNA Repair Mutations Can Help Guide Treatment Selection and Predict Response in Preoperative Breast Cancer

Press Release ASCO 2015 - Radio Therapy

Abstract No: 1008, Monday June 1, 3:00 PM to 6:00 PM

Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials.

Press release - German Breast Group (GBG) Retrospective Analysis Shows Continued Value of Radiotherapy in Breast Cancer Patients despite Advances in Chemotherapy

News

  • 04.06.2018 ASCO: GeparNuevo Presentation

    GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.

    Mehr ...
  • 13.03.2018 ESMO 2019

    ESMO 2019

    ESMO Breast Cancer congress ist taking place in May 2019 in Berlin, Germany.

    Mehr ...
  • 02.02.2018 Informationsvideo für Patienten

    Prof. Loibl, Leiterin der GBG und Prof. Jackisch, Chefarzt am Sana Klinikum Offenbach sprechen mit einer Patientin über ihre Erfahrungen in einer klinischen Studie.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd